California Public Employees Retirement System Acquires 4,239 Shares of Medpace Holdings, Inc. $MEDP

California Public Employees Retirement System lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.8% during the first quarter, HoldingsChannel reports. The firm owned 52,363 shares of the company’s stock after acquiring an additional 4,239 shares during the quarter. California Public Employees Retirement System’s holdings in Medpace were worth $25,144,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of MEDP. AQR Capital Management LLC increased its position in shares of Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after acquiring an additional 404,226 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares in the last quarter. Franklin Resources Inc. increased its holdings in Medpace by 158.6% during the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after purchasing an additional 183,645 shares in the last quarter. Norges Bank acquired a new stake in shares of Medpace in the 4th quarter valued at about $102,156,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Medpace by 92.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after purchasing an additional 166,654 shares during the period. Institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the subject of a number of research reports. Robert W. Baird reiterated a “neutral” rating and set a $547.00 price objective (up from $477.00) on shares of Medpace in a report on Wednesday, July 8th. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and upped their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Royal Bank Of Canada decreased their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Barclays lowered their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a report on Friday, April 24th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $473.09.

Medpace Price Performance

Medpace stock opened at $528.12 on Thursday. The firm has a market cap of $15.08 billion, a PE ratio of 33.19, a price-to-earnings-growth ratio of 2.66 and a beta of 1.15. The stock’s fifty day moving average price is $484.63 and its two-hundred day moving average price is $493.49. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.53 million. During the same quarter last year, the business posted $3.10 EPS. The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insider Activity

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.